FDA weighs peptides-as-supplements shift amid industry push
Supplement makers urged FDA to classify peptides including BPC-157 as dietary ingredients, opening a second path to legal U.S. access separate from 503A compounding.
May 11, 2026 · 3 min read
Alongside the better-known 503A compounding review scheduled for July, a separate regulatory debate has been running largely below the radar: whether compounds like BPC-157 should qualify as lawful dietary supplement ingredients. Supplement industry groups pushed that case directly to the FDA at a public meeting in March 2026, and the agency's top food official signaled at least some openness.
What happened
The FDA convened a public meeting in March 2026 to examine the scope of what ingredients can go into dietary supplements. Representatives from the supplement industry used that forum to advocate for peptides — including compounds currently categorized as unapproved drugs — being reclassified as dietary ingredients, which would allow them to be sold over the counter without a prescription or physician involvement.
FDA Deputy Commissioner for Food Kyle Diamantas, speaking at the meeting, described the administration's goals as including "cutting out red tape," a comment that observers read as openness to broadening the category of allowable supplement ingredients. No specific rule change was announced at the meeting, and any formal rulemaking would require a public comment period and agency action.
The push represents a distinctly different legal theory from the 503A compounding pathway that has dominated peptide regulatory coverage this year. Dietary supplements are governed by the Dietary Supplement Health and Education Act (DSHEA), which sets a low evidentiary bar compared to drug approval — manufacturers do not need to prove safety or efficacy before a product reaches shelves, though they may not make disease claims.
Science News covered the push in early May 2026, reporting that the petition would take the industry further into "buyer-beware land," in the words of critics who worry that supplement access would remove even the limited physician oversight that the compounding route requires.
Why it matters
The 503A compounding route, which requires a licensed physician's prescription and use of a licensed pharmacy, is the pathway the peptide community has closely tracked through the April Category 2 removal and the July PCAC meeting. The dietary supplement route is qualitatively different: it would allow peptides to be sold directly to consumers in stores or online without any prescriber involvement.
Jensen Jose, senior regulatory counsel at the nonprofit Center for Science in the Public Interest, argued against expansion: "FDA should focus on making the current market safer instead of allowing more chemicals and substances in supplements." The Department of Defense's Operation Supplement Safety program separately notes that BPC-157 is "not a dietary ingredient" and "cannot be legally prescribed or sold over the counter" under current law — language that would need to change for a supplement pathway to open.
The risk calculus differs significantly depending on which pathway becomes available. Compounded peptides require physician oversight, sterile manufacturing standards, and individualized prescriptions. OTC dietary supplements require none of those. For compounds like BPC-157 that lack published human safety trials, that distinction carries real weight.
What to watch
- Whether the FDA follows the March meeting with a formal Advance Notice of Proposed Rulemaking or other regulatory action on dietary supplement ingredients
- Whether any peptides are specifically named in draft rulemaking as proposed dietary ingredients
- Congressional response: the SAFE Drugs Act (H.R.6509) would explicitly prohibit selling research chemicals biologically identical to FDA-approved drugs without an NDA, which could preempt a supplement pathway for some compounds
- How the two regulatory tracks — 503A compounding and dietary supplements — interact if both advance simultaneously
Sources
Sources